Paragon Care Director Carmen Riley Awarded Nearly 6 Million Performance Rights Following Shareholder Approval

Carmen Riley’s Performance Rights Holding Nearly Doubles After July 2026 Allocation

Following the grant on 3 July 2026, director Carmen Riley’s performance rights in Paragon Care Limited rose significantly. Previously holding 7,480,252 rights, the addition of 5,996,911 represents an approximate 80% increase, bringing her total to 13,477,163 performance rights. Her direct ownership of 2,538,888 ordinary shares remains unchanged.

The change was reported via an Appendix 3Y Change of Director’s Interest Notice, confirming the nature of the transaction as a performance rights grant. No cash consideration was paid, consistent with typical executive and director incentive arrangements where rights are awarded as non-cash remuneration linked to future performance targets.

Shareholder Approval Secured at November 2024 AGM Prior to Grant

The issuance of the 5,996,911 performance rights was approved by shareholders at Paragon Care’s Annual General Meeting on 21 November 2024. Shareholders voted on the proposed grant to Riley, with the resolution passing successfully. The formal grant date, however, was 3 July 2026, over 18 months after the shareholder approval.

This time gap aligns with common Australian corporate practices, where performance rights grants follow structured timelines reflecting regulatory compliance, board discretion, and the start of performance measurement periods. Paragon Care’s adherence to seeking shareholder approval prior to issuing equity-linked remuneration demonstrates compliance with governance standards.

Understanding Performance Rights in Paragon Care’s Director Pay Structure

Performance rights are widely used in Australian listed companies as long-term incentives. Unlike options, these rights generally have no exercise price, entitling holders to ordinary shares upon meeting specified performance or service conditions. This mechanism aligns directors’ interests with shareholders by linking remuneration value to the company’s share price and achievement of defined goals.

The company’s update does not specify the vesting criteria, performance hurdles, or expiry dates for the 5,996,911 rights granted to Riley. Details on whether conditions are market-based, non-market-based, or mixed were not disclosed. Investors seeking further information should consult the remuneration report in Paragon Care’s latest annual report or the explanatory documents from the 21 November 2024 AGM.

Riley’s Ordinary Shareholding Remains Constant at 2,538,888 Shares

While Riley’s performance rights have increased markedly, her direct holding of ordinary shares remains at 2,538,888, unchanged since the last notice filed on 5 January 2026. No ordinary shares were bought or sold in connection with this grant.

This distinction is important for investors evaluating director alignment: ordinary shares represent current economic ownership, whereas performance rights are contingent on future vesting. The combination of both holdings is a common ASX practice to balance immediate ownership with incentives tied to future performance.

No Closed Period Trading Concerns Reported in Director’s Notice

The Appendix 3Y filing confirms that no securities were traded during a closed period, which is a restricted timeframe around financial results when directors and insiders must obtain clearance before dealing in company securities. This assurance indicates compliance with Paragon Care’s securities trading policy and relevant ASX Listing Rules and Corporations Act provisions governing director disclosures.

Role of the Performance Rights Grant Within Paragon Care’s Remuneration Framework

Paragon Care, a diversified healthcare solutions provider in Australia and New Zealand, designs its board remuneration structures to reflect the long-term nature of its business and value creation objectives. Equity-linked incentives like performance rights serve to retain and motivate key governance personnel.

The nearly six million performance rights granted to Riley represent a significant figure for investors monitoring potential dilution and the company’s incentive arrangements. Although total performance rights across all directors and executives were not disclosed, Riley’s cumulative holding now exceeds 13.4 million rights. Should all vest and convert, this would notably impact the company’s share register depending on total shares outstanding at vesting.

Regulatory Disclosure Obligations Under ASX and Corporations Act

Filing an Appendix 3Y is required under ASX Listing Rule 3.19A.2, mandating prompt notification of changes in directors’ relevant interests. The relevant change date here is 3 July 2026, with the notice lodged within the required timeframe.

Additionally, section 205G of the Corporations Act 2001 requires companies to notify ASIC of such changes. The Appendix 3Y filing fulfills both ASX and ASIC disclosure requirements, with the company acting as agent for the director. This dual filing approach is standard among ASX-listed entities to ensure transparency for regulators and the market.

Investor Outlook: Monitoring Vesting Milestones and Director Interest Updates

Investors should focus on when and under what conditions Riley’s 13,477,163 performance rights might vest. Vesting would lead to the issuance of new ordinary shares, affecting earnings per share and total share count. Performance rights also signal confidence from the board and shareholders in the company’s long-term prospects.

It will also be important to watch for similar grants to other directors or executives, as multiple Appendix 3Y filings can reveal broader equity remuneration trends. Key upcoming events include further director interest disclosures, the release of Paragon Care’s financial year annual report, and any updates on performance rights vesting provided through remuneration reports or market announcements.

AGM Approval Highlights Paragon Care’s Commitment to Shareholder Engagement and Governance

The requirement and receipt of shareholder approval at the 21 November 2024 AGM emphasize Paragon Care’s focus on involving shareholders in remuneration decisions. Under ASX Listing Rule 10.14, shareholder approval is mandatory before issuing equity securities to directors under employee incentive schemes. This approval granted a clear mandate for the performance rights issued to Carmen Riley.

This governance process is particularly relevant amid heightened scrutiny of director pay in Australia. Institutional investors and proxy advisors increasingly evaluate whether equity grants include meaningful performance conditions and are proportionate to company size and performance. While this update does not detail the performance hurdles, investors can find such information in the AGM notice and explanatory materials from November 2024.